A PHASE 1, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CC-94676 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
January 18, 2021
End Date
January 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
January 18, 2021
End Date
January 14, 2026